CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity-Reference-Cited by-同舟云学术

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

Published:2020-11-09 Issue:1 Volume:2 Page:34-48
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Watt April C.^ORCID,Cejas Paloma,DeCristo Molly J.,Metzger-Filho Otto,Lam Enid Y. N.^ORCID,Qiu Xintao^ORCID,BrinJones Haley,Kesten Nikolas^ORCID,Coulson Rhiannon,Font-Tello Alba,Lim Klothilda,Vadhi Raga,Daniels Veerle W.,Montero Joan^ORCID,Taing Len,Meyer Clifford A.,Gilan Omer,Bell Charles C.^ORCID,Korthauer Keegan D.,Giambartolomei Claudia^ORCID,Pasaniuc Bogdan,Seo Ji-Heui,Freedman Matthew L.^ORCID,Ma Cynthia^ORCID,Ellis Matthew J.,Krop Ian,Winer Eric,Letai Anthony^ORCID,Brown Myles,Dawson Mark A.^ORCID,Long Henry W.^ORCID,Zhao Jean J.^ORCID,Goel Shom^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s43018-020-00135-y.pdf

Reference64 articles.

1. Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6, 353–367 (2016).

2. Spring, L. M. et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395, 817–827 (2020).

3. Finn, R. S. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77 (2009).

4. Goel, S. et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 29, 255–269 (2016).

5. Herrera-Abreu, M. T. et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 76, 2301–2313 (2016).

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells;PLOS ONE;2024-08-28

3. A Dual Bispecific Hydrolysis Peptide‐Drug Conjugate Responsive to Micro‐Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple‐Negative Breast Cancer;ChemBioChem;2024-08-20

4. HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells.;2024-07-03

5. Abemaciclib-induced epithelial-mesenchymal transition mediated by cyclin-dependent kinase 4/6 independent of cell cycle arrest pathway;The International Journal of Biochemistry & Cell Biology;2024-07